OF
AMLX icon

Optimize Financial’s Amylyx Pharmaceuticals AMLX Stock Holding History

Optimize Financial’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Sell
31,890
-111
-0.3% -$1.72K 0.21% 106
2026
Q1 		$445K Buy
+32,001
New +$450K 0.22% 153

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Optimize Financial's AMLX Position: Q2 2026 in Review

Optimize Financial reduced its Amylyx Pharmaceuticals (AMLX) stake by 0.35% in Q2 2026, selling an estimated $1.72K and leaving 31,890 shares worth $573K. The position accounts for 0.21% of the portfolio, ranked #106.

Optimize Financial first reported a position in AMLX in Q1 2026 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Optimize Financial held 31,890 shares of Amylyx Pharmaceuticals worth $573K as of Q2 2026.
  • Optimize Financial sold 111 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.72K.
  • Amylyx Pharmaceuticals made up 0.21% of Optimize Financial's portfolio in Q2 2026, its #106 holding.
  • Optimize Financial first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Optimize Financial's 13F filing for Q2 2026, filed 27 Aug 2026.